tbuckley/cabot-search huggingface dataset:
18F-FDG PET/CT in Renal Infections
Authors: Maxime Morelle, Alice Jaillard, Dimitri Bellevre, Guillaume Collet, Grégory Petyt
Journal: Clinical Nuclear Medicine (2016)

A 58-year-old paraplegic patient was prescribed 18F-FDG for persistent inflammatory syndrome after aortic surgery for dissection. The examination was performed on a Siemens mCT Flow PET/CT and shows a moderate prostate uptake, related to prostatitis on self-catheterization and a focal renal cortical hypermetabolism of the left medial midpole of a horseshoe kidney, which corresponds to renal parenchyma on the CT, and suggests pyelonephritis, confirmed by 99mTc-DMSA SPECT/CT.
Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis
Authors: F Thol, S Klesse, L Köhler, R Gabdoulline, A Kloos, A Liebich, M Wichmann, A Chaturvedi, J Fabisch, V I Gaidzik, P Paschka, L Bullinger, G Bug, H Serve, G Göhring, B Schlegelberger, M Lübbert, H Kirchner, M Wattad, D Kraemer, B Hertenstein, G Heil, W Fiedler, J Krauter, R F Schlenk, K Döhner, H Döhner, A Ganser, M Heuser
Journal: Leukemia (2016)
P1.45: Impact of Dose Adjustment on Afatinib Safety and Efficacy in EGFR Mutation-Positive NSCLC: Post-Hoc Analyses of LUX-Lung 3/6
Authors: Carlos H. Barrios, Yi-Long Wu, James Chih-Hsin Yang, Lecia V. Sequist, Sarayut L. Geater, Tony Mok, Cheng-Ping Hu, Nobuyuki Yamamoto, Kenneth O’Byrne, Shun Lu, Vera Hirsh, Martin Sebastian, Isamu Okamoto, Riyaz Shah, Angela Märten, Dan Massey, Sven Wind, Martin Schuler
Journal: Journal of Thoracic Oncology (2016)
P0822 : Safety And efficacy of sofosbuvir containing regimens for hepatitis C: Community treatment of a real world population with advanced liver fibrosis
Authors: D. Ouzan, T. Fontanges, G. Pénaranda, P. Delasalle, M. Antoni, S. Bresson-Hadni, P. Cerdan, S. Beorchia, P. Toulemonde, N. Boyer, C. Castelnau, J.-P. Jacques, B. Serge, C. Bonny, S. Boussoukouya, H. Joly, B. Hanslik
Journal: Journal of Hepatology (2015)
SAT0398 Application of Disease Activity Index for Psoriatic Arthritis (DAPSA) in A Cohort of Patients Followed in The Institute of Rheumatology Prague
Authors: J. Stolfa, L. Sedova
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> At present new guidelines for the therapy and monitoring of psoriatic arthritis are in progress, inspired by the EULAR guidelines 2015. We propose the Minimal Disease Activity (MDA) as a target of therapy. Given the fact that the major problem of our patients is joint manifestation of psoriatic disease (PD) and only occassionally severe skin syndrome, which usually requires different therapeutic approach we have searched for an instrument which would assess the severity of joint involvement numerically, taking into account the patient9s point of view. For this purpose we used the recently validated index DAPSA<sup>1</sup> <h3>Objectives</h3> (1) To ascertain the correlation of this index with its individual components (2) to take a look at the development of this index over time in a sample of patients from our database. <h3>Methods</h3> We picked 53 cases out of our database of 216 patients, who had at least 6 yearly controls with full set of data available. Subsequently we calculated DAPSA according to the formula: SJC+TJC+pat.pain VAS10,0cm+pat. Global VAS10,0cm+CRPmg/l<sup>1</sup>. Then we determined the correlation between DAPSA and individual components of the index using Pearson9s correlation coefficient for each of 6 controls (C). We followed further the development of this index during the course of 6 years and calculated the percentage of patients who achieved remission (REM), low disease activity (LDA), moderate disease activity (MDA), or high disease activity (HDA) according to this index. The usual treatment algorythm was used, only the more tight control was employed. <h3>Results</h3> (1) The best correlation with DAPSA was found for CRP (0,74–0,93) and to a lesser degree for the number of swollen and tender joints (0,50–0,72 and 0,49–0,70 respectively) and for patient reported outcomes (pat. global-0,57–0,75 and pat. pain-0,44–0,61). (2) The proportion of patients in REM and LDA increased linearly during the 6-year follow up. (3) The average DAPSA score decreased during their follow-up (21,1–3,59). <h3>Conclusions</h3> The newly validated index of disease activity DAPSA seems to be a good indicator of disease activity and treatment response in patients with psoriatic arthritis. It could be a good component of local guidelines for treatment and monitoring of PsA. <h3>References</h3> Schoels M, Aletaha D, Alasti F, et al. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis2015. <h3>Acknowledgement</h3> Supported by the Research program of the Ministry of health of Czech Republic: IGA MZ CR: No. 000 000 23728 <h3>Disclosure of Interest</h3> None declared
Circulating Bcma Binding to Its Ligand BAFF Prevents Normal Antibody Production in Multiple Myeloma Patients
Authors: Eric Sanchez, Abigail Gillespie, Nika M Harutyunyan, George Tang, Jillian Gottlieb, Suzie Vardanyan, Mingjie Li, Claudia Andreu-Vieyra, Michael Ghermezi, Cathy Wang, Joseph Ben-Zvi, Gigi Garzio, Judith Finlay, Benjamin Bonavida, Haiming Chen, James R. Berenson
Journal: Blood (2014)
Impact of AVR on LV Remodeling and Function in Paradoxical Low-Flow, Low-Gradient Aortic Stenosis With Preserved LVEF
Authors: Abdellaziz Dahou, Marie-Annick Clavel, Jean G. Dumesnil, Romain Capoulade, Henrique B. Ribeiro, Kim O'Connor, Patrick Mathieu, Jonathan Beaudoin, Éric Larose, Josep Rodés-Cabau, Philippe Pibarot
Journal: JACC. Cardiovascular imaging (2016)
The MYOCAN Study. A Phase II Study of Cyclophosphamide, Oncovin, Myocet™, and Prednisone Plus Rituximab (R-COMP) in the Treatment of Elderly Patients with Diffuse Large B-Cell Non-Hodgkin Lymphoma (DLBCL).
Authors: Massimo Federico, Martin J.S. Dyer, Maria Dolores Caballero, Claire Reilly, Eckhard Thiel
Journal: Blood (2004)
AB0528 Organ Involvement with Systemic Vasculitis of Autoimmune and of Septic Origin – A Comparative Postmortem Study of 38 Rheumatoid Arthritis Patients:
Authors: Ά. Apáthy, M. Bély
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> In rheumatoid arthritis (RA) circulating immune complexes lead to systemic vasculitis of autoimmune origin (A-SV) which may involve various organs. RA as well as autoimmune diseases may be complicated by septic infections (SI) and accompanied with systemic vasculitis of infectious origin (S-SV). In case of systemic vasculitis the identification of its origin is of crucial importance because of the basic differences in therapy. <h3>Objectives</h3> The aim of this study was to compare the prevalence, average incidence and severity of A-SV and S-SV in various organs of RA patients. <h3>Methods</h3> At the National Institute of Rheumatology 12138 patients died between 1969 and 2000; among them 234 with RA and all of them were autopsied. Lethal septic infection (SI) was observed in 31 (13.25%) of 234 patients. SI was accompanied in 5 patients with S-SV. The clinically identified pathogenic agents and the strong, significant and positive correlation between S-SV and SI (association coefficient: 1, c<sup>2</sup>=26.1881, p&lt;0.00007) supported the infectious origin of SV. The prevalence, average incidence and severity of S-SV in twelve organs of these 5 RA patients was determined histologically and compared with 33 RA patients with A-SV of our previous study [1]. <h3>Results</h3> The prevalence in % and the average incidence and severity of A-SV (n=33) and S-SV (n=5) in various organs of 38 RA patients are summarized in the table. <h3>Conclusions</h3> The involvement (prevalence in %) of various organs, the average incidence and severity of A-SV and S-SV are basically determined by the systemic circulation and blood supply of various organs, by circulating immune complexes and other agents, furthermore by their possible elimination. The source of infection may have a modifying effect regarding the organ manifestation of S-SV. <h3>A-SV</h3> was most dominant in the heart, skeletal muscles, lung, pancreas, and kidneys, the main targets of circulating immune complexes in RA. In septic RA patients the S-SV dominated in the heart, skeletal muscles, kidneys, and gastrointestinal tract, which may be due to the complex effect of circulation and source of septic infection (e.g. high prevalence of urogenital and gastrointestinal infections in our autopsy population). <h3>References</h3> Bély M, Apáthy Άgnes. Clinical pathology of rheumatoid arthritis: Cause of death, lethal complications and associated diseases in rheumatoid arthritis. 1–440 pp. Akadémiai Kiadό, Budapest 2012 http://www.akkrt.hu/p&gt; <h3>Disclosure of Interest</h3> None declared
Outcome of Patients with Chronic Myeloid Leukemia with T315I BCR-ABL Mutation
Authors: Kati a BB Pagnano, Rosana A Silveira, Luciana Nardinelli, Monika Conchon, Carmino De Souza, Pedro ED Llacer, Irene Lorand-Metze, Vaneuza Funke, Ricardo Pasquini, Cintia C Mascarenhas, Maria Aparecida Zanichelli, Nelma CD Clementino, Israel Bendit
Journal: Blood (2008)
Prognositc Inpact of Tumor-Infiltrating Cells Especially CD163 Positive Macrophage in DLBCL Treated with R-CHOP
Authors: Naoe Goto, Nobuhiro Kanemura, Hisashi Tsurumi, Nobuhiko Nakamura, Senji Kasahara, Takeshi Hara, Hisataka Moriwaki, Tsuyoshi Takami
Journal: Blood (2011)
FRI0479 Efficacy of Colchicine and IL-1 Inhibitors in Amyloidosis Associated with Familial Mediterranean Fever: A Retrospective Analysis
Authors: B. Toz, S. Tacar, E. Oguz, M. Erdugan, B.A. Esen, S. Kamali, L. Ocal, B. Erer, A. Gül
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Familial Mediterranean fever (FMF), the most common form of hereditary autoinflammatory diseases, is associated with increased risk for secondary (AA) amyloidosis <h3>Objectives</h3> We herein aimed to investigate the features of FMF patients with amyloidosis with respect to their responses to current therapies <h3>Methods</h3> We enrolled FMF patients with amyloidosis who were regularly followed-up for at least 6 months between 1978 and 2015 into the study. Starting times for colchicine, anakinra or canakinumab and treatment responses were noted. Proteinuria (spot urine protein/creatinine ratio) and C-reactive protein (CRP) levels were measured in every three months of follow-up. Partial response was defined as ≥50% decrease in baseline proteinuria accompanied by a normal serum creatinine level, whereas complete response was defined as &lt;0.3 gr/d baseline proteinuria and stable serum creatinine. Correlations between treatment responders and continuously elevated or normalized CRP levels were tested by using a chi-square test <h3>Results</h3> We identified 79 FMF patients with documented secondary amyloidosis, and all were on colchicine treatment. Their demographic features are shown in Table 1. Mean time to diagnosis after the first symptom was 10 years. Patients were evaluated for partial and complete response after mean follow-up period of 66±85 months. Response to colchicine was observed in 30/65 patients [partial response in 19 (29%), complete response in 11 (17%)]; and 54% was non-responder to colchicine. Anakinra was added to treatment in 22 patients with inadequate response to colchicine, which resulted in partial response in 12, and complete response in 2. Eight patients with partial response to colchicine also received anakinra for better control of attacks and/or elevated acute phase response, and a complete response was achieved in 3 patients. In 3 patients, anakinra was switched to canakinumab because of local injection site reaction (1 patient) and persistence of proteinuria (2 patients). Among those, two patients had partial response, and another underwent hemodialysis due to progressive kidney failure. No significant association was observed between normalized CRP levels and response to treatment with respect to proteinuria and creatinine levels (colchicine; p=0.67, anakinra/canakinumab;p=0.82). No serious infection requiring hospitalization was detected in association with IL-1 blockade. <h3>Conclusions</h3> Amyloidosis still remains as an important complication of FMF, and a satisfactory response to colchicine could be observed in an important proportion of patients. Treatment with IL-1 inhibitors seems to be an effective and safe option for those patients with an inadequate response to colchicine <h3>Disclosure of Interest</h3> None declared
Gram-negative bacteremia
Journal: JAMA (1968)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Induction with Bortezomib and Dexamethasone (BD) Followed By Risk Adapted High Dose Melphalan and Autologous Stem Cell Transplantation and BD Consolidation in Patients with AL Amyloidosis: A Phase II Feasibility Study
Authors: Heather Landau, Nicole Montanez, Alexandra Cowan, Hoover Elizabeth, Carlos Flombaum, Jennifer Liu, Mat Maurer, Nikoletta Lendvai, Ola Landgren, Sergio A. Giralt, Hani Hassoun
Journal: Blood (2015)
Purified CD4 T Lymphocyte Infusion Can Result in Graft-Versus-Leukemia Reactivity without Gvhd by Recognition of Broadly Expressed Minor Histocompatibility Antigens in HLA Class-II
Authors: P. van Balen, C.A.M. van Bergen, I. Jedema, S.A.P. van Luxemburg-Heijs, J.C. Harskamp, H.M. van Egmond, S.A.J. Veld, M. Griffioen, W.A.F. Marijt, C.J.M. Halkes, J.H.F. Falkenburg
Journal: Blood (2012)
Long-Term Follow-Up Confirms the Benefit of All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (As2O3) as Front Line Therapy for Newly Diagnosed Acute Promyelocytic Leukemia (APL).
Authors: Yuan-Fang Liu, Yong-Mei Zhu, Zhan-Zhong Shi, Jun-Min Li, Li Wang, Yu Chen, Zhi-Xiang Shen, Jiong Hu
Journal: Blood (2006)
Tibetan Gain-of-Function Variant of Prolyl Hydroxylase 2 (EGLN1) and Selected SNPs of HIF-2-Alpha (EPAS1) Are Associated with Lower Hemoglobin Values in Tibetans
Authors: Tsewang Tashi, N. Scott Reading, Anna Shestakova, Tatiana Burjanivova, Tanna Uran, Felipe R Lorenzo V, Hao Hu, Chad Huff, Lorna Moore, Parvaiz Koul, Carl T Wittwer, Victor R. Gordeuk, Re-Li Ge, Josef T. Prchal
Journal: Blood (2015)
Single Cell Whole Transcriptome Analysis Reveals Distinct Molecular Signatures of Therapy-Resistant Chronic Myeloid Leukemia Stem Cells
Authors: Alice Giustacchini, Supat Thongjuea, Petter S. Woll, Paul Sopp, Ana Duenas Perez, Nikolaos Barkas, Christopher Booth, Ruggiero Norfo, Sally-Ann Clark, Lauren Jamieson, Sten Eirik Jacobsen, Adam Mead
Journal: Blood (2015)
Increased Bone Marrow Erythroid Precursors Is Associated with Shorter Survival in Low-Grade Myelodysplastic Syndromes.
Authors: Hesham M. Amin, Sherry A. Pierce, Hagop M. Kantarjian, Michael J. Keating, Emil J. Freireich, Charles A. Koller, Miloslav Beran, Maher Albitar, Susan M. O’Brien, Elihu H. Estey
Journal: Blood (2004)
Mitonuclear Interactions Mediate Transcriptional Responses to Hypoxia in<i>Drosophila</i>
Authors: Jim A. Mossman, Jennifer G. Tross, Nick A. Jourjine, Nan Li, Zhijin Wu, David M. Rand
Journal: Molecular Biology and Evolution (2016)

Among the major challenges in quantitative genetics and personalized medicine is to understand how gene × gene interactions (G × G: epistasis) and gene × environment interactions (G × E) underlie phenotypic variation. Here, we use the intimate relationship between mitochondria and oxygen availability to dissect the roles of nuclear DNA (nDNA) variation, mitochondrial DNA (mtDNA) variation, hypoxia, and their interactions on gene expression in Drosophila melanogaster. Mitochondria provide an important evolutionary and medical context for understanding G × G and G × E given their central role in integrating cellular signals. We hypothesized that hypoxia would alter mitonuclear communication and gene expression patterns. We show that first order nDNA, mtDNA, and hypoxia effects vary between the sexes, along with mitonuclear epistasis and G × G × E effects. Females were generally more sensitive to genetic and environmental perturbation. While dozens to hundreds of genes are altered by hypoxia in individual genotypes, we found very little overlap among mitonuclear genotypes for genes that were significantly differentially expressed as a consequence of hypoxia; excluding the gene hairy. Oxidative phosphorylation genes were among the most influenced by hypoxia and mtDNA, and exposure to hypoxia increased the signature of mtDNA effects, suggesting retrograde signaling between mtDNA and nDNA. We identified nDNA-encoded genes in the electron transport chain (succinate dehydrogenase) that exhibit female-specific mtDNA effects. Our findings have important implications for personalized medicine, the sex-specific nature of mitonuclear communication, and gene × gene coevolution under variable or changing environments.
Improvement in Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplantation Upon Administration of Mesenchymal Stem Cells From Third-Party Donors: A Pilot Prospective Study
Authors: Qifa Liu, Xiaodan Liu, Meiqing Wu, Yanwen Peng, Xiaoyong Chen, Jing Sun, Fen Huang, Zhiping Fan, Hongsheng Zhou, Xiuli Wu, Guopan Yu, Xian Zhang, Yonghua Li, Yang Xiao, Chaoyang Song, Peng Xiang
Journal: Blood (2012)
The Impact of Rituximab in the Development of Acute Graft Versus Host Disease (GVHD) Following Allogeneic Stem Cell Transplantation (SCT) for Acute Lymphoblastic Leukemia (ALL).
Authors: Partow Kebriaei, Rima M. Saliba, Carrie Ma, Cindy Ippoliti, Daniel R. Couriel, Marcus de Lima, Sergio Giralt, Muzaffar H. Qazilbash, James L. Gajewski, Chul S. Ha, Richard E. Champlin, Issa F. Khouri
Journal: Blood (2005)
Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK –Positive Human Non–Small Cell Lung Cancer
Authors: Kyoung Ho Pyo, Sun Min Lim, Hye Ryun Kim, Young Hoon Sung, Mi Ran Yun, Sung-Moo Kim, Hwan Kim, Han Na Kang, Ji Min Lee, Sang Gyun Kim, Chae Won Park, Hyun Chang, Hyo Sup Shim, Han-Woong Lee, Byoung Chul Cho
Journal: Journal of Thoracic Oncology (2016)
Clinical Characteristics, Treatment Response and Prognosis Index for 379 Pediatric Acute Lymphoblastic Leukemia Cases Treated By Cclg-2008 Protocol
Authors: Yi-xin HU, Yi-huan Chai, Hailong He, Jun LU, Yi WANG, Wenli Zhao, Peifang Xiao, Jun-jie Fan, Shaoyan Hu
Journal: Blood (2014)
Erythropoietin Stimulates Bone Formation In Vivo By Targeting Both HSCs and MSCs
Authors: Younghun Jung, Anne Ziegler, Yusuke Shiozawa, Zhuo Wang, Junhui Song, Jianhua Wang, Jincheng Wang, Michael J. Pienta, Clara H. Lee, Aaron M. Havens, Elisabeth A. Pedersen, Paul H. Krebsbach, Russell S. Taichman
Journal: Blood (2008)
AB0394 Early Effect of Tofacitinib on Osteoclast Regulator in Rheumatoid Arthritis
Authors: M. Kitano, S. Kitano, M. Sekiguchi, N. Azuma, N. Hashimoto, S. Tsunoda, K. Matsui, H. Sano
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The selective Janus kinase (JAK) inhibitor tofacitinib has demonstrated excellent efficacy for rheumatoid arthritis (RA). These results suggest the possibility that tofacitinib improves osteoclastic bone destruction of RA. However, the detailed mechanism of tofacitinib for osteoclastogenesis in RA is pooly understood. In this study, we investigated the effect of tofacitinib on serum biomarkers related to osteoclast regulation such as soluble receptor activator of NF-kappa B ligand (sRANKL) and osteoprotegerin (OPG) in patients with RA. <h3>Objectives</h3> To clarify the effect of tofacitinib on osteoclast regulator in RA. <h3>Methods</h3> Fourteen patients with active RA who inadequate response to disease-modifying antirheumatic drugs (DMARDs) (mean age: 54.6 years, mean disease duration: 4.1 years, mean simplified disease activity index: 26.9, ACPA positive: 86%, oral steroid use: 29%, mean oral steroid dose: 10mg/day, MTX use: 93%, mean MTX dose:10.9mg/week, biologic DMARDs naïve: 57%) were started on treatment with tofacitinib 5mg twice daily (BID). Disease activity was assessed using the 28-joint count disease activity score-C-reactive protein sedimentation rate (DAS28-CRP) and simplified disease activity index (SDAI). Next, circulating levels of sRANKL and OPG were examined by enzyme-linked immunosorbent assay (ELISA) (sRANKL: human RANKL ELISA kit, Biomedica, OPG: human osteoprotegerin ELISA kit, Biomedica respectively) at the baseline, week 2, 4 and 12. <h3>Results</h3> After treatment of tofacitinib, SDAI score among all fourteen patients decreased significantly from 26.9±12.4 (mean±SD) at the baseline to 14.7±9.9 at week 4 (<i>p</i>&lt;0.0001), to 8.3±6.1 at week 12 (<i>p</i>&lt;0.0001). Baseline levels of sRANKL were significantly correlated with the levels of CRP (Spearman r<sup>2</sup>=0.488, P=0.0054). Average of sRANKL levels decreased immediately from 0.15±0.11 pmol/L at the baseline to 0.09±0.05 pmol/L at week 2 (<i>p</i>=0.0097), to 0.11±0.10 pmol/L at week 4 (<i>p</i>=0.0311), to 0.08±0.05 pmol/L at week 12 (<i>p</i>=0.0014). On the other hand, statistically significant changes in OPG levels were not observed during 12 weeks. Consequently, average of sRANKL/OPG ratio decreased significantly from 4.81±4.82 at the baseline to 2.62±1.84 at week 2 (<i>p</i>=0.0186), to 3.11±2.81 at week 4 (<i>p</i>=0.0191), to 2.11±1.72 at week 12 (<i>p</i>=0.0052). Interestingly, decreasing effects of sRANKL levels or sRANKL/OPG ratio were greater in patient with high sRANKL level at the baseline. <h3>Conclusions</h3> Here, we show for the first time that tofacitinib has improved inflammatory bone destruction immediately through the regulation of sRANKL levels and sRANKL/OPG balance in RA. This mechanism might be a control of RANKL induction via JAK pathway inhibition in activated CD4+ T cells and synovial fibroblasts <h3>Disclosure of Interest</h3> None declared